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clinical laboratories to develop a "receptor profile" 
for patients undergoing endocrine therapies. Recently, 
the need has arisen to develop an "ionic profile" of the 
estrogen receptor so that more precise assignments can 
be made concerning endocrine therapies. In this work, a 
DEAE-cellulose chromatography column was used to 
separate the ionic forms o{ the murine estrogen receptor 
by high performance_ ion-exchange chromatography (HPIEC). 
Cytosols from murine uteri were incubated for 1-2 hours 
with [ 3HJ17B-estradiol, cleared of unbound ligand, and 
applied to .an anion-exchange column. Components were 
eluted at pH 7,4 using a gradient of phosphate buffer 
and sodium chloride buffer at 0-4 degrees Celsius. Each 
salt buffer system eluted the various isoforms 
iii 
differently, however, both systems eluted peaks in the 
0-400 mM range of the gradient. Four isoforms were found 
with each buffer system. Also, each isoform could be 
found to elute at nearly the same fraction number under 
different states of activation, which demonstrates that 
the isoforms are stable under different incubation 
conditions. In general, the results obtained show fair 
reproducibility, good recovery, and demonstrates that 
high performance ion-exchange liquid chromatography has 
an apparent role in the purification of proteins where 
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INTRODUCTION 
Estrogenic steroid hormones have many sites of 
action including the uterus, hypothalamus, liver, and 
kidney [l]. They exert their effects by passing thro~gh 
the cell membrane, interacting with a cytoplasmic binding 
protein, and, as an activated binding complex, 
translocating to the nucleus where interaction with 
chromatin presumably initiates certain events responsible 
for alterations in the rates of transcription, 
translation, and even replication [2]. 
The estrogen binding protein content of human 
breast cancers has been used to predict the responsiveness 
of patients to endocrine therapy [2,4-6]. According to 
Wittliff et al [3], 55% to 65% of primary breast tumors 
and 45% to 55% of metastatic breast tumors contain more 
than 10 fmol/mg cytosol protein of estrogen receptors. In 
this work, the estrogen binding protein is referred to as 
the estrogen "receptor" and the assays performed on these 
proteins develop a "receptor profile" for the patient 
undergoing the endocrine therapy [3]. 
The estrogen receptor has been studied by several 
methods such as 1) charcoal-dextran assays, 2) hydroxyl-
1 
2 
apatite method, 3) sucrose gradient sedimentation, and 4) 
electrophoretic analysis [2,7]. One disadvantage that 
these methods share is the time involved to run these 
assays (e.g. some require overnight incubation and/or 
centrifugation). Proteolysis and many degradative changes 
can take place while these procedures are being performed. 
One method of estrogen receptor analysis that 
requires little time for preparation and is used 
extensively is high performance liquid chromatography 
(HPLC). While there are many types of HPLC, the most 
widely used has been size-exclusion HPLC. This offers a 
rapid and reproducible means by which a biopsy sample 
can be analyzed for "receptor positive" status [8]. 
Using size-exclusion HPLC, it has been found that 
the estrogen receptor can exist in different forms, call-
ed isoforms, depending on the conditions under which the 
sample is prepared for HPLC analysis. Using sedimentation 
analysis, the qualitative relationships between the 
different receptors of the rat uterus have been 
determined: cytoplasmic aggregated ~8S, deaggregated ~4S, 
trypsinized ~3.6S; nuclear ~5S. While the estrogen 
receptor is mainly referred to as being cytoplasmic, 
Pavlik et al [9], using DNAase and several protease 
inhibitors, presented results indicating that a large 
nuclear receptor exists which displays different 
3 
characteristics than the cytoplasmic receptor. This 
nuclear receptor was isolated from chromatin and, under 
the conditions used, had a molecular weight greater than 
669,000. The intact, non-deaggregated cytoplasmic receptor 
has a molecular weight of 90-110,000 [9]. 
"Activation" is a term used in estrogen receptor 
research to describe certain characteristics of the 
estrogen receptor in in vitro experiments [10]. The 
"activated" receptor displays a change in ligand 
dissociation kinetics from fast to slow [10], faster 
nuclear translocation, and a higher affinity for chromatin 
[2-5]. Activation can be visualized in a chromatogram by 
noting a transfer in distribution from one isoform to 
another (Figure 1). The rat uterine estrogen-receptor 
complex can be activated in vitro by increasing time or 
temperature of incubation with ligand or by the addition 
of nucleoside triphosphates [10]. Addition of 10 mM 
molybdate to cytosol inhibits activation of receptor 
complexes by some ill-defined mechanism [2-5,10-14]. Since 
molybdate is a phosphatase inhibitor, activation may 
involve dephosphorylations [11]. 
Receptor activation also alters the surface 
charge of the receptor probably as a result of exposure of 
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Figure 1. Example showing activation of receptor with 
size-exclusion chromatography. Activation causes a shift 
in proportion from Peak B to Peak A. 
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of receptor [10]. Ion-exchange chromatography is used to 
investigate the ionic characteristics of the estrogen 
receptor. While most HPLC buffer systems used in estrogen 
receptor research favor a neutral pH (7.0-7.4), high 
salts, and the addition of dimethylformamide, ion-exchange 
buffer systems also utilize a salt concentration gradient 
in the system which allows the visualization of different 
ionic forms of the receptor. By developing an "ionic 
profile" of the estrogen receptor, more precise 
assignments can be made concerning endocrine therapies. 
Materials and Methods 
Materials 
Radiolabeled steroid, 17~-[2,4,6,7-3H4]estradiol 
(104-115 Ci/mmol), was obtained from New England Nuclear, 
Boston, MA 02118. The following biochemicals were used: 
sodium acetate, potassium phosphate monobasic, potassium 
phosphate dibasic, tris acetate, dextran C (Fisher 
Scientific, Fair Lawn, NJ 07410). Sodium molybdate 
(Mallinckrodt, Co.,St. Louis, MO 63134), tris, ultra pure 
grade (Schwarz/Mann,Cleveland, OH 44128), dimethyl-
formamide (Burdick & Jackson Chemicals, Muskegon, MI. 
49442), ethylenediamine-tetraacetic acid, sodium azide, 
and sodium chloride were from Sigma Chemical Co., st. 
Louis, MO 63178. Protease inhibitors, phenylmethyl 
sulfonyl fluoride, pepstatin A, aprotinin, leupeptin, and 
ethylenediamine-tetraacetic acid (EDTA) were from 
Boehringer Mannhein Biochemicals, Indianapolis, Ind. 
46250. Immature CF-1 mice (Harlan-Sprague-Dawley, 
Indianapolis, IN 46229) were obtained at 19-23 days of age 
and killed within seven days. Millex GV filters (25 mm in 
diameter, 0.22 um pore size) were from Millipore Corp., 




The concentration of K2HPO4 was varied between 
1000 mmol/L (P1000) and 10 mmol/L (P10), but the pH was 
kept at 7.0. All elution buffers contained 75 ml of dime-
thylformamide per liter. All buffers were membrane 
filtered with Millipore HATF ultrafiltration membranes 
to remove particulates. 
Preparation of Cytosols 
Mice were sacrificed by cervical dislocation 
and decapitation to bleed out any blood-borne hormones. 
Freshly removed uteri, freed of fat and mesenteric 
tissue, were homogenized with a Brinkman Polytron 
Homogenizer in buffer according to protocol (five uteri 
per milliliter of buffer)(Table 1). After centrifugation 
at 3200 x g on a Beckman J6-B ICL centrifuge at 0 degrees 
Celcius for 30 minutes to remove the nuclear-myofibrillar 
material, the supernatant was recentrifuged on a Beckman 
L8-70 Ultracentrifuge at 45 000 x g for 30 minutes at 0 
degrees Celsius. The supernate obtained at the higher 
speed was mixed with sodium molybdate (50 mmol/L, final 
concentration). See table l for layout of experiment. 
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Receptor Determinations. 
Estrogen receptor preparations were 
supplemented with 10 nmol of [ 3HJestradiol per liter to 
determine total binding activity. Dextran-coated 
charcoal (5 g of charcoal and 0.5 g of Dextran C in 100 
mL of 10 mmol/L Tris buffer) was added to remove unbound 
ligand, one volume of the charcoal slurry to nine 
volumes of cytosol. The radioactivity not absorbed was 
regarded as "bound" radioactivity. For liquid 
scintillation counting, "Scinti Verse E" fluor (Fisher 
Scientific Co., Fairlawn, NJ 07410), was used ( 2 ml in 
a 5 ml counting vial) and quench was automatically 
corrected for each sample on a Beckman Scintillation 
Counter with each sample being counted for 1 minute. 
Size-exclusion Chromatography 
Supernates from high-speed centrifugation were 
filtered through membrane filters with low protein-
binding properties (Millex GV), to remove components 
that impair column performance. For isocratic elution, a 
flow metered pump (Model 112; Beckman Instruments, 
Berkley, CA 94710) was used to deliver buffer to a 
Spherogel-TSK exclusion column G-4000,21.5 X 600 mm; 
Beckman Instruments) fitted with a guard column 
(Spherogel-TSK precolumns SW, 21.5 x 100 mm). 
9 
Samples were injected with a syringe-loaded 
injector (Model 210; Beckman Instruments) fitted with a 
250-ul sample loop, then steroid receptors were eluted 
with Pl00 buffer containing 75 mL of dimethylformamide 
per liter. One mL fractions of column effluent were 
collected with a rapid response programmable fraction 
collector (Foxy;Isco Co.). The chromatographic system 
was maintained and operated at 2 to 5 degrees C. All 
samples contained 20 mM sodium molybdate and were run 
with and without protease inhibitors (see materials 
used). 
Anion-exchange Chromatography 
Supernates from high-speed centrifugation were 
filtered through membrane filters with low protein 
binding properties (Millex GV) to remove components that 
impair column performance. To deliver a gradient buffer 
system, a Waters 650 Advanced Protein Purification 
System fitted with a 250-ul sample loop was used. A 
waters 650 System controller delivered buffer and sample 
to a diethyl-aminoethyl (DEAE) column (21.5 x 100 mm, 
Millipore Corp., waters Div., Milford, Mass., 01757). 
One ml fractions were collected on an Isco (Model 211) 
fraction collector. 
Table 1. Experimental protocol for preparation of 
cytosol~. All manipulations were performed at 0-4 
degrees Celsius t9 prevent activation of receptor. 
1. Sacrifice,dissect uteri 
2. Homogenize (5 uteri/ml) 
3. Slow spin (3200 x g, 15 min) 
4. Collect supernatant 
5. Fast spin (45000 x g, 30 min) 
6. Divide into tubes Band c 
7. Incubate with [ 3HJ-estradiol 
(according to following schedule) 
10 
0-4deg 25deg 37deg 
Bl 120min 
0-4deg 25deg 37deg 
*Cl 120min 
B2 60min 60min 
B3 120min 120min 
*C2 60min 60min 
*C3 120min 120min 
* add 10 ul/ml of 
protease inhibitors 
(see materials) 
8. Remove unbound ligand 
(dextran-coated charcoal) 
9. Divide samples in half 
10. Size-exclusion and anion-exchange chromatography 
11. Collect 1 ml fractions 
12. Count activity 
11 
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Figure 2. Salt gradient of Buffer B for anion-exchange 
chromatography. The gradient was determined using uracil 
as a marker and tracing its flow with an absorbance 
detector (280 nm). 
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Each gradient system consisted of a dual buffer. 
Buffer A and Buffer B contained identical biochemicals, 
except that Buffer B contained an additional salt, either 
potassium phosphate or sodium chloride. The ion-exchange 
system was equilibrated for approximately 20 minutes with 
Buffer A before the initiation of daily experimentation 
and between each run. Uracil was used alone as an 
absorbance marker (280 nm) to trace the gradient of salt 
in the system (Figure 2). See Table 2 for buffer systems 
used. 
Table 2. Buffer systems used for anion-exchange 
chromatography. Bold print denotes salt used to interact 
with column and compete for binding sites with estrogen-
receptor complex. EDTA, ethylenediamine-tetraacetic acid; 
DTT, dithiothrietol; DMF, dimethylformamide. 
Pl000 SYSTEM NaCl SYSTEM 
Buffer A Buffer B Buffer A Buffer B 
Pl0 Pl000 20 mM Tris 20 mM Tris 
1.5 mM EDTA 1,5 mM EDTA 1 mM EDTA 1 mM EDTA 
1 mM DTT 1 mM DTT 1 mM DTT 1 mM DTT 
7.5 % DMF 7,5 % DMF 7.5 % DMF 7.5 % DMF 
pH 7.0 pH 7.0 1 M NaCl 
13 
Data Management 
Lotus 1-2-3 software was used to manipulate 
data and to create graphs for ease in representation of 
peaks. It was also used to determine the position of 
peaks using the @max functions and to calculate the 
relative percentages of each peak. 
RESULTS and DISCUSSION 
Size-Exclusion Chromatography 
Chromatographs show activation of Peaks A and B 
with little change in Peak C (Figures 3,4) . There was an 
obvious transfer of proportion of Peak B to Peak A when 
the sample was subjected to an increase in time or 
temperature of incubation. The use of protease 
inhibitors caused a minor shift in proportion of Peak B 
to Peak A at a lower incubation temperature (Figures 
5, 6) . 
In both systems used, Peaks A, B, and c were 
found to elute at or near a common fraction. This was 
also found in previous work done by Pavlik et al. The 
peak representing the largest isoform, Peak A, eluted at 
fraction 13 . A slightly smaller isoform, Peak B, eluted 
at fraction 18, and Peak C eluted at fraction 24 . By 
running ligand without receptor, it was determined that 
ligand not removed by dextran-coated charcoal eluted at 
positions 28-40 (results not shown) . 
Size-exclusion chromatography, in this work 
and in previous experiments, has been used as a control 
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Figure 3. Size-exclusion chromatography showing activa-
tion of peaks due to increase in time and temperature of 
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Figure 4. Relative proportions of peaks A,B, and C from 
figure 3. Note shift in proportion from Peak B to Peak A. 
androgen receptors of various tissues [14-17]. Size-
exclusion chromatography offers a rapid, reproducible 
means by which many tissues can be assayed in a 
relatively short time. Therefore, degradation and 
proteolysis are less of a contributing factor in the 
variability of chromatographs. 
Anion-Exchange Chromatography 
17 
The Pl000 system eluted 4 distinct peaks in 
each of the chromatograms. While all peaks eluted at 
less than 400 mM of salt, each peak could be found in 
particular areas of the salt gradient. Ao mM peak was 
found at fraction number 6 in chromatograms of both 
systems. A -47 mM peak occured very shortly after 
initiation of the salt gradient. An intermediate -180 mM 
peak and a high salt species, or -383 mM peak was 
eluted. Since the gradient is not constant, the fraction 
number corresponding to the mM of salt at which the peak 
eluted is used for statistical purposes (Table 3). The 
-180 mM and -383 mM species generally carried the 
majority of proportion (Figure 7,8). There was an 
apparent increase in peaks 0 mM and -47 mM 
species with the use of protease inhibitors (Figure 
18 
9,10). The NaCl system also eluted 4 peaks in each 
chromatograph, however, in different positions than did 
the Pl000 system. There was a 0 mM peak eluting at 
fraction number 6, as in the Pl000 system. A -55 mM peak 
eluted shortly after initiation of the gradient. Follow-
ing a peak at -234 mM salt was a high salt -428 mM 
species. As in the Pl000 system, the corresponding 
fraction numbers are used for statistical purposes 
(Table 3). Peaks 0 mM and -428 mM carried the majority 
of proportion with a more even distribution of all 
isoforms with activation or the use of protease 
inhibitors (Figures 11-14). 
Table 3. Simple statistical analysis of elution fractions. 
Abbreviations : x, mean; s.d., standard deviation. 
Pl000 SYSTEM ( n=4) NaCl SYSTEM ( n=4) 
Peak (mM) Fraction Peak (mM) Fraction 
0 X=6, s.d.=0 0 X=6, s.d.=0 
-47 X=32, s.d.=3.32 -55 X=34, s.d.=7.00 
-180 X=66, s.d.=12.02 -234 X=80, s.d.=12.22 
-383 X=l00, s.d.=5.63 -429 X=l04, s.d.=8.56 
while there is some variability in the elution of 
fractions of peaks, ion-exchange high performance 
chromatography offers a rapid and fairly reproducible 
means by which proteins can be separated or purified. 






















D ODEG I 20MIN 
10 20 
MINUrES OR FRACTION NO. 
t 25DEG 60MIN 
30 
◊ 25DEG I 20MIN 
19 
40 
Figure 5. Size-exclusion chromatography showing acti-
vation of peaks due to increase in time and temperature 
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Figure 6. Relative proportion of peaks A,B, and C from 
figure 5, Note shift in proportion from Peak B to Peak A. 
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indicative of proteins which do not interact with the 
column on the basis of their surface charge, although on 
anion exchangers both the porosity and the 
hydrophobicity of the stationary phase may influence 
retention characteristics. This same early peak has also 
been found to elute with other anion exchange columns, 
such as the AX-300 [17]. Anion-exchange columns such as 
the AX-500 and the AX-1000 did not exhibit this early 
peak before initiation of the salt gradient. This early 
peak could be more precisely described by slowing down 
the flow rate of buffer through the system and by 
modifying the salt gradient. 
While the murine estrogen receptor showed 4 
isoforms, this is not the case in all animals and even 
varies with the use of different anion-exchange columns 
[17]. Wittliff et al have shown that a human breast 
cancer biopsy displayed 3 isoforms on the AX-300 and 
only one isoform on the AX-1000. A rat mammary gland 
showed 2 isoforms on the AX-300 and AX-1000, but only 
one on the AX-500. Each isoform eluted at a different 
position on individual columns. 
It is evident from Table 3 that the NaCl system 
required more salt to elute receptor than did the PlOOO 
system. This phenomenon can be described in light of the 
22 
fact that the PlOOO system has a higher negative charge 
than does the NaCl system. Also worth mentioning is the 
large variability in the -180 mM and the -234 mM 
isoforms of the PlOOO and the NaCl system, respectively. 
This third peak could be more susceptible to proteolysis 
than the other peaks. The elution characteristics of 
ligand without receptor (results not shown) demonstrated 
little or no interaction with the DEAE column. Ligand 
not removed by dextran-coated charcoal showed poor 
resolution and added little, if any, to isoform peaks. 
While recovery of receptor was generally good 
(Figure 15), several chromatograms showed poor recovery. 
This low recovery can be attributed to at least 2 
factors, namely (a) a retention of receptor molecule on 
the column or (b) a loss of ligand or "stripping" of 
the ligand from the receptor [17). An answer to these 
problems may be provided through the use of affinity 
labeled ligands, post-column labeling, and/or monoclonal 
antibodies to the receptor molecule [17), 
This work has demonstrated for the first time 
that the isoforms of the murine estrogen receptor can be 
described using ion-exchange high performance liquid 
chromatography. These experiments are the first in a 
long line of experiments designed to ultimately describe 
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Figure 7. Anion-exchange chromatography showing acti-
vation of receptor due to increase in time and 
temperature of incubation with PlOOO system. Note 
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Figure 8. Relative proportions of isoforms from figure 7. 
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Figure 9. Anion-exchange chomatography showing acti-
vation of receptor due to increase in time and 
temperature of incubation (37 deg) with PlOOO system. 
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Figure 10. Relative proportions of isoforms from figure 
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Figure 11. Anion-exchange chromchromatography showing 
activation of pe_aks due to increase in time and · 
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Figure 12. Relative proportions of isoforms from figure 
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Figure 13. Anion-exchange chromatography showing 
activation due to increase in time and temperature of 
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Figure 14. Relative proportions of isoforms from figure 






Figure 15. Recovery of receptor from anion-exchange 
column. Experiment 1-3: Refer to figures 9-14 for time 
and temperature of incubations. Bars A,B,C, and D 
coincide with figures 7,9,11, and 13, respectively. 
work described here will serve as an aid not only in 
describing the ionic forms of the murine estrogen 
receptor, but will also help to determine the best 
buffer system in eluting the various ionic forms. 
32 
Much work has yet to be done to determine the 
validity of this work. For example, the effects of 
sodium and potassium on the murine estrogen receptor 
have yet to be described, for it is well known that many 
enzyme systems are dependent on sodium and potassium. 
With more experimentation, an ionic profile can be made 
of the estrogen receptor which will lead to a more 
precise assignment of endocrine therapies for patients 
suffering from estrogen dependent cancers. 
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